Rivoglitazone clinical trials
Includes 3 studies of Rivoglitazone hydrochloride.
How each study uses rivoglitazone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2007 (4)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2007 | 4 |
| 2010 | 1 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Daiichi Sankyo (3) · Santen Inc. (2) · Daiichi Sankyo Co., Ltd. (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses rivoglitazone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Study of Rivoglitazone in Type 2 Diabetes MellitusCompletedPhase 3Daiichi SankyoNCT00484198Written as RivoglitazoneHow we know
- Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes MellitusTerminatedPhase 3Daiichi SankyoNCT00571519Written as Rivoglitazone HClHow we know
- Placebo and Active Controlled Study of Rivoglitazone in Type 2 DiabetesCompletedPhase 2/3Daiichi SankyoNCT00143520Written as RivoglitazoneHow we know
- A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye PatientsCompletedPhase 2Santen Inc.NCT01468168Written as DE-101 Ophthalmic SuspensionHow we know
- Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye PatientsCompletedPhase 1/2Santen Inc.NCT01118754Written as DE-101 ophthalmic suspensionHow we know
- Placebo Controlled Dose-Response Study of Rivoglitazone in Type 2 DiabetesCompletedPhase 2Daiichi Sankyo Co., Ltd.NCT00575471Written as Rivoglitazone HClHow we know
- Placebo and Active Comparator Controlled Dose Response Study of Rivoglitazone in Type 2 DiabetesCompletedPhase 2Daiichi Sankyo Co., Ltd.NCT00575874Written as Rivoglitazone HClHow we know
Codes
What other systems call rivoglitazone · ClinicalTrials.gg INT005133
- MeSH (NLM) C521549rivoglitazoneOne source NLM
- UNII (FDA) 3A3N0634Q6RIVOGLITAZONEConfirmed FDA, NLM, Wikidata
- Wikidata Q7338968(RS)-rivoglitazoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C72841RivoglitazoneOne source FDA
- DrugBank DB09200One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C521549 | rivoglitazone | One source NLM |
| UNII (FDA) | 3A3N0634Q6 | RIVOGLITAZONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7338968 | (RS)-rivoglitazone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C72841 | Rivoglitazone | One source FDA |
| DrugBank | DB09200 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.